



28 May 2020

Support Services



Source: Refinitiv

Market data

EPIC/TKR	FLTA
Price (p)	107
12m High (p)	245
12m Low (p)	42
Shares (m)	29
Mkt Cap (£m)	31
EV (£m)	33
Free Float*	33%
Market	AIM

*As defined by AIM Rule 26

Description

Filta Group provides cooking oil filtration, fryer and drain management services in North America and Europe to commercial kitchens.

Company information

CEO	Jason Sayers
CFO	Brian Hogan
Chairman	Tim Worledge
	+44 1788 550100
	www.filtapl.com

Key shareholders

Directors	66.4%
Gresham House	12.6%
Blackrock	5.6%
Cannacord Genuity	4.5%

Diary

Sep'20	Interim results
--------	-----------------

FILTA GROUP

FY'19 results and COVID-19 update

Filta Group (Filta) announced FY'19 results pretty much in line with our numbers. Adjusted EBITDA was £3.2m, vs. our £3.3m estimate, and revenue was £24.9m, vs. our £25.1m expectation. These figures confirmed that the integration of Watbio was back on track and the business was trading well until COVID-19 struck. Most of Filta's customers are currently closed, but the company is optimistic that they will bounce back once distancing restrictions are lifted. We have removed our 2020 forecasts.

- **FY'19 results:** Revenue was up 75%, at £25m, of which £8.6m came from Watbio. Costs, however, were up 91%, leaving reported EBIT down a third, at £1.2m, and statutory PBT nearly halved, to £0.9m. The company ended the year with net borrowings of £2.1m, having paid the deferred acquisition and integration costs of Watbio, and including future lease liabilities.
- **1Q'20 trading and outlook:** 2020 had started well in all territories, with six new franchisees added. Margin improvements were coming through. A significant part of the company's activities is focused on the hard-hit leisure sector and, until it reopens, the company is mostly marking time. It has developed a bacterial cleansing service, which it is offering to existing and new clients.
- **Valuation:** Along with our forecasts, we have suspended our valuation.
- **Risks:** The clear risk for Filta is that it loses a substantial part of its business if customers are unable to reopen. In the UK-owned operations, the business is heavily weighted towards 20 large operations that are well positioned to survive, including some supermarket chains that have remained open.
- **Investment summary:** Filta is an attractive business, in our view, combining the capital-light franchise model in North America and Europe with company-owned operations in the UK. As businesses begin to reopen, the focus on cleanliness, efficiency and environmental friendliness is unlikely to be abated.

Financial summary and valuation

Year-end Dec (£000)	2015	2016	2017	2018	2019	2020E
Revenue	7,925	8,469	11,547	14,213	24,923	
Adjusted EBITDA	594	1,193	2,116	2,642	3,163	
Underlying EBIT	450	1,011	2,059	1,941	1,504	
Reported EBIT	450	-249	1,699	1,782	1,208	
Underlying PTP	376	932	1,968	1,900	1,233	
Statutory PTP	376	-329	1,608	1,742	936	Forecasts suspended
Underlying EPS (p)	1.39	3.66	5.05	5.39	2.40	
Statutory EPS (p)	1.39	-1.51	3.85	4.88	1.39	
Net (debt)/cash	-619	3,271	2,992	2,040	-879	
Shares issued (m)	22	23	27	29	29	
P/E (x)	139.7	53.0	38.4	36.0	44.5	
EV/EBITDA (x)	72.1	34.2	23.6	20.5	10.1	

Source: Hardman & Co Research

Analyst

Jason Streets 020 7194 7622
js@hardmanandco.com

Profit & Loss

Income statement, 2015-20E						
Year-end Dec (£000)	2015	2016	2017	2018	2019	2020E
Revenue	7,925	8,469	11,547	14,213	24,923	
Cost of sales	-4,208	-4,449	-5,870	-7,131	-14,756	
Gross profit	3,718	4,019	5,677	7,083	10,166	
Other income	36	25	38	25	191	
Distribution costs	-84	-80	-125	-151	-203	
Admin. expenses	-3,220	-2,953	-3,532	-5,015	-8,650	
Operating profit	450	1,011	2,059	1,941	1,504	
<i>Adjusted EBITDA</i>	<i>594</i>	<i>1,193</i>	<i>2,116</i>	<i>2,642</i>	<i>3,163</i>	
Finance expenses	-74	-80	-91	-40	-271	
Underlying PBT	376	932	1,968	1,900	1,233	
Exceptional costs		-1,261	-360	-159	-296	
Tax	-74	-101	-590	-422	-532	
PAT	302	-430	1,017	1,320	404	
Discontinued ops.		87	33	19		
Net profit	302	-343	1,050	1,339	404	
Exchange differences	-45	-186	-94	-29	-149	
Comprehensive income	257	-528	956	1,309	255	Forecasts suspended
Avg. no. of shares (fully-dil., m)	21.8	22.7	27.3	27.4	29.0	
EPS (p)	1.4	-1.5	3.9	4.9	1.4	
Statutory EPS (fully-dil., p)	1.4	-1.5	3.9	4.9	1.4	
Underlying EPS (fully-dil., adj., p)	1.4	3.7	5.1	5.4	2.4	
DPS (p)			1.3	1.6	2.0	
Gross profit margin	47%	47%	49%	50%	41%	
Admin. as % of revenue	41%	35%	31%	35%	35%	
EBIT margin	6%	12%	18%	14%	6%	
Tax rate	20%	11%	30%	22%	43%	
Growth YoY						
Revenue	20%	7%	36%	23%	75%	
Operating profit	45%	125%	104%	-6%	-23%	
PBT	64%	148%	111%	-3%	-35%	
EPS	63%	164%	38%	7%	-55%	

Source: Hardman & Co Research

Balance sheet

Balance sheet, 2015-20E						
@ 31 Dec (£000)	2015	2016	2017	2018	2019	2020E
Non-current assets						
Property, P,P&E	1,121	1,191	1,216	1,493	1,336	
Intangible assets	90	167	485	7,186	1,270	
Right of use asset					6,515	
Goodwill			631	1,640	1,640	
Contract acquisition costs	170		157	343	416	
Deposits	2	3	2	2	5	
Trade receivables	215	379	302	325	412	
Deferred tax assets	520	756	652	755	678	
Total non-current assets	2,117	2,495	3,446	11,744	12,272	
Current assets						
Trade receivables	1,591	1,961	2,311	4,821	4,065	
Contract acquisition costs			38	52	57	
Inventories	299	288	438	1,386	1,760	
Cash	979	4,392	4,031	6,790	2,891	
Total current assets	2,870	6,641	6,818	13,049	8,773	
Assets held for sale		88	74			
Total assets	4,987	9,224	10,339	24,793	21,045	
Current liabilities						
Trade payables	-1,726	-1,990	-2,143	-6,510	-3,261	
Borrowings	-597	-104	-108	-841	-793	Forecasts suspended
Due to directors/deferred consideration	-1,522					
Deferred income	-194	-401	-533	-869	-534	
Lease liability					-333	
Total current liabilities	-4,039	-2,495	-2,783	-8,220	-4,921	
Non-current liabilities						
Borrowings	-1,001	-1,018	-932	-3,909	-2,977	
Deferred income	-1,555	-2,310	-2,405	-2,791	-2,496	
Deferred tax			-95	-1,291	-1,159	
Lease Liability					-882	
Total non-current liabilities	-2,556	-3,328	-3,432	-7,992	-7,515	
Liabilities held for sale		-33	-66			
Total liabilities	-6,595	-5,856	-6,281	-16,211	-12,435	
Net assets	-1,609	3,368	4,057	8,582	8,610	
Equity						
Share capital	380	2,695	2,713	2,892	2,909	
Share premium		3,480	131	3,372	3,659	
Accumulated losses/profits	-1,914	-2,257	1,863	2,711	2,548	
Other reserves	-75	-551	-650	-394	-506	
Total equity	-1,609	3,368	4,057	8,582	8,610	

Source: Hardman & Co Research

Cashflow

Cashflow, 2015-20E						
Year-end Dec (£000)	2015	2016	2017	2018	2019	2020E
Operating activities						
Statutory PBT	376	-218	1,641	1,760	936	
Finance costs	74	80	91	42	271	
Depreciation	90	119	110	187	217	
Amortisation	54	63	100	212	1,180	
Other	9	49	97	310	272	
Working capital changes	17	-53	-197	-490	-2,078	
Cash from operations	620	40	1,842	2,021	799	
Tax paid	-54		-510	-1,216	-486	
Net cash from operations	566	40	1,332	805	313	
Investing activities						
Purchase of P,P&E	-180	-43	-113	-316	-288	
Purchase of intangibles	-60	-154	-55	-105	-177	
Sales of assets	64		25	49	40	Forecasts suspended
Acquisitions			-1,138	-3,738	-1,800	
Net investing cash	-176	-197	-1,281	-4,110	-2,225	
Financing activities						
Issue of shares		3,999	149	2,870	32	
Net borrowings	291	-146	-47	3,538	-1,168	
Interest paid	-70	-105	-91	-42	-227	
Dividends paid			-226	-372	-558	
Net financing cash	221	3,748	-215	5,994	-1,921	
Net change in cash	611	3,591	-165	2,689	-3,834	
Cash at beginning of year	452	979	4,392	4,031	6,790	
FX	-84	-178	-196	70	-65	
Cash at end of year	979	4,392	4,031	6,790	2,891	

Source: Hardman & Co Research

Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legals/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: 'The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.



research@hardmanandco.com

35 New Broad Street
London
EC2M 1NH

+44(0)20 7194 7622

www.hardmanandco.com